NCT05539430 is a Phase 1, open label, dose escalation, multicenter study to evaluate Claudin 18.2-targeting CAR-T cells (LB1908) in adult patients with unresectable, locally advanced or metastatic ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths worldwide ...